CAR natural killer cells for AML that has come back
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a type of immune cell (CAR NK cells) that targets a protein called CD33 on leukemia cells. It is for children and young adults with AML that has relapsed or not responded to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have AML that has come back or not gone away after treatment
- You are between 1 and 39 years old (first few patients must be at least 16)
- You have a donor identified for a stem cell transplant if needed
- Your heart, liver, kidneys, lungs, and brain are working well enough
- You agree to use birth control if applicable and to a long-term follow-up study
- You have not had certain other cancer treatments in the past few weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests donated “natural killer (NK) cells,” a type of immune cell, in children and young adults with AML that has come back or did not respond to treatment. It mainly looks at safety and also studies whether the treatment can help control the leukemia.
This trial tests a new type of immune cell therapy (CAR-T) that targets three proteins (CLL1, CD33, NKG2D) on leukemia cells in patients with acute myeloid leukemia that has not responded to or come back after prior treatment.
This trial tests a natural killer (NK) cell therapy that targets a protein called CLL1 on leukemia cells. It aims to help people whose acute myeloid leukemia (AML) has come back or not responded to other treatments.
This trial tests a therapy made from your own immune cells, engineered to target a marker called CLL-1 on leukemia cells, for people whose AML has come back or hasn't responded to standard treatments.
This trial tests a new natural killer (NK) cell therapy for adults with acute myeloid leukemia (AML) that has returned or not responded to treatment. The therapy targets two specific markers (CLL1 or CD33) on leukemia cells. It aims to see if these immune cells can safely fight the cancer.
This trial tests a lab-made immune cell treatment (CAR-T) made to target AML cells with a specific marker (NKG2D ligand). It’s for people whose acute myeloid leukemia (AML) has come back or didn’t respond to standard chemotherapy.
Hear when a new Relapsed/Refractory AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.